TABLE 1.
Clinical characteristics and outcomes of the Lisofylline and Respiratory Management of Acute Lung Injury (LARMA), Statins for Acutely Injured Lungs from Sepsis (SAILS) and the University of Pittsburgh Acute Lung Injury Registry and Biospecimen Repository (ALIR) cohorts
| LARMA | SAILS | ALIR | |
| Patients | 218 | 224 | 107 |
| Age years | 49 (37–66) | 57 (43–64) | 56 (44–65) |
| Male | 135 (62) | 107 (48) | 57 (53) |
| Self-reported race | |||
| White | 168 (77) | 171 (76) | 103 (96) |
| Black | 36 (17) | 38 (17) | 4 (4) |
| Other | 14 (6) | 11 (5) | 0 |
| Unknown | 0 | 4 (2) | 0 |
| Medical history | |||
| AIDS | 13 (6.0) | 7 (3.1) | |
| Immune suppression | 26 (11.9) | 41 (18.3) | 19 (17.8) |
| Cirrhosis | 4 (1.8) | 16 (7.2) | 10 (9.3) |
| Leukaemia | 2 (0.9) | 16 (7.1) | |
| Solid tumour malignancy | 3 (1.4) | 10 (4.5) | 4 (3.7) |
| Baseline severity of illness | |||
| Sepsis | 76 (35) | 188 (84) | 93 (87) |
| mSOFA score# | 8 (6–10) | 9 (7–11) | 8 (5–9) |
| Outcomes | |||
| VFD | 19 (0–25) | 20 (0–25) | 6 (0–14) |
| 28-day mortality | 61 (29) | 57 (25) | 32 (30) |
| 60-day mortality | 69 (35) | 66 (29) | 40 (37) |
Data are presented as n, median (interquartile range) or n (%). mSOFA: modified sequential organ failure assessment score; VFD: ventilator-free days. #: mSOFA in LARMA and SAILS reflects the unimputed score for the six components comprising the SOFA score. There were no data on vasopressor dosage in the LARMA cohort; therefore, a modified haemodynamics score (0=mean arterial pressure (MAP) >70 mmHg, 1=MAP <70 mmHg on no vasopressors or MAP >70 mmHg and on vasopressors, 2=MAP <70 mmHg and on vasopressors) was used for both LARMA and SAILS cohorts. The mSOFA score in ALIR does not include the neurological component; therefore, the maximum score is 20.